全球细胞免疫疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

细胞免疫疗法市场预计将从 2025 年的 148.7 亿美元成长到 2034 年的 935.2 亿美元，2026 年至 2034 年的复合年增长率为 22.67%。

由于癌症发病率上升和对标靶治疗的需求不断增长，全球细胞免疫疗法市场正经历显着增长。 CAR-T细胞疗法和先进基因编辑技术的创新正在改变肿瘤治疗，并提高患者的存活率。生物技术研究投入的增加、临床试验的扩大以及监管部门的核准支持正在加速商业化进程。製药公司正在加强产能以满足不断增长的需求。未来几年，非肿瘤适应症的拓展和同种异体移植技术的进步预计将推动全球市场持续成长。

骨髓恶性肿瘤和固态肿瘤率的不断上升仍然是市场成长的主要驱动力。细胞工程和加工技术的进步有助于提高治疗效果和安全性。政府和私营机构正在加大对研究倡议的投入，以加速创新。生物技术公司与学术机构之间的策略合作正在加强产品平臺。已开发国家完善的健保报销机制有助于提高病患的用药可近性。随着人们对个人化医疗的认识不断提高，对客製化免疫疗法的需求将持续稳定成长。

精准医疗的日益普及正在改变全球治疗模式。细胞处理和生产的自动化有助于降低成本并扩充性。强有力的临床证据表明，持续缓解的疗效正在增强医疗服务提供者的信心。生物製药公司正在投资研发下一代即用型疗法，以扩大治疗的可及性。新兴市场的医疗基础设施正在逐步完善，创造了新的成长机会。持续的研发和技术改进正在为细胞免疫疗法市场的长期永续发展奠定基础。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球细胞免疫疗法市场：依治疗方法类型划分

• 市场分析、洞察与预测
• CAR-T细胞疗法
• 树突细胞疗法
• NK细胞疗法
• TIL疗法
• 其他的

第五章 全球细胞免疫疗法市场：依适应症划分

• 市场分析、洞察与预测
• B细胞恶性肿瘤
• 摄护腺癌
• 肝癌
• 肾臟细胞癌
• 其他的

第六章：全球细胞免疫疗法市场：依最终用途划分

• 市场分析、洞察与预测
• 医院
• 癌症研究所
• 其他的

第七章 全球细胞免疫疗法市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Novartis AG
  • Gilead Sciences Inc.（Kite Pharma）
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • GlaxoSmithKline Plc
  • AstraZeneca
  • Pfizer Inc
  • Johnson & Johnson
  • Celyad
  • Adicet Bio Inc
  • Dendreon Pharmaceuticals LLC

The Cellular Immunotherapy Market size is expected to reach USD 93.52 Billion in 2034 from USD 14.87 Billion (2025) growing at a CAGR of 22.67% during 2026-2034.

The global cellular immunotherapy market is witnessing significant growth due to the rising prevalence of cancer and increasing demand for targeted treatment approaches. Innovations in CAR-T cell therapy and advanced gene-editing technologies are transforming oncology care and improving patient survival rates. Growing investments in biotechnology research, expanding clinical trials, and supportive regulatory approvals are accelerating commercialization. Pharmaceutical companies are enhancing manufacturing capabilities to meet rising demand. In the coming years, expanding indications beyond oncology and advancements in allogeneic therapies are expected to drive sustained market expansion worldwide.

Rising incidences of hematological malignancies and solid tumors remain key drivers of market growth. Technological advancements in cell engineering and processing techniques are improving therapeutic efficacy and safety profiles. Governments and private organizations are increasing funding for research initiatives to accelerate innovation. Strategic collaborations between biotech firms and academic institutions are strengthening product pipelines. Improved reimbursement frameworks in developed countries are enhancing patient access. As awareness of personalized medicine grows, demand for customized immunotherapies will continue to expand steadily.

The increasing focus on precision medicine is reshaping global treatment paradigms. Automation in cell processing and manufacturing is helping reduce costs and improve scalability. Strong clinical evidence demonstrating durable remission benefits is building confidence among healthcare providers. Biopharmaceutical companies are investing in next-generation off-the-shelf therapies to broaden accessibility. Emerging markets are gradually improving healthcare infrastructure, creating new growth opportunities. With continuous research and technological refinement, the cellular immunotherapy market is poised for long-term sustainable development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• CAR T Cell Therapy
• Dendritic Cell Therapy
• NK Cell Therapy
• TIL Therapy
• Others

By Indication

• B-cell Malignancies
• Prostate Cancer
• Liver Cancer
• Renal Cell Carcinoma
• Others

By End Use

• Hospitals
• Cancer Institutes
• Others

COMPANIES PROFILED

• BristolMyers Squibb Company, , Novartis AG, Gilead Sciences Inc Kite Pharma, F HoffmannLa Roche Ltd, Merck KGaA, GlaxoSmithKline plc, AstraZeneca, Pfizer Inc, Johnson Johnson, Celyad, Adicet Bio Inc, Dendreon Pharmaceuticals LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. CAR T Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dendritic Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NK Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. TIL Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. B-cell Malignancies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Renal Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Indication
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Indication
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Indication
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Indication
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Indication
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CELLULAR IMMUNOTHERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Gilead Sciences Inc. (Kite Pharma)
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 Merck KGaA
  • 9.2.5 GlaxoSmithKline Plc
  • 9.2.6 AstraZeneca
  • 9.2.7 Pfizer Inc
  • 9.2.8 Johnson & Johnson
  • 9.2.9 Celyad
  • 9.2.10 Adicet Bio Inc
  • 9.2.11 Dendreon Pharmaceuticals LLC